Direct Answer: Prior Authorization Savings Are Real, but Not Guaranteed
Prior authorization can reduce avoidable claims spending by checking medical necessity, covered benefits, provider credentials, and applicable utilization rules before expensive treatment begins. However, “prior authorization cost savings” should not be treated as a fixed percentage of a payer’s or provider’s budget. Savings depend on the accuracy of the rules, the services being reviewed, the denial rate, the appeal rate, and how quickly decisions are returned. Research cited by AJMC has identified approximately $20 billion in broader healthcare cost-saving opportunities, but that figure should not be presented as a direct prior authorization savings estimate.
Also worth reading: How Should Health Organizations Build a Prior Authorization ROI Model? · How Should Payers and Providers Measure Prior Authorization Performance in 2026? · How Do Prior Authorization Appeals Work, and How Can Healthcare Operations Teams Reduce Denials?
The financial case is strongest when a prior authorization program prevents genuinely unnecessary services while preserving medically appropriate care. Weak programs can create administrative costs, delayed treatment, member dissatisfaction, provider rework, and appeals that may offset any avoided spending. A study described by PR Newswire found delays in elective spine surgery without evidence of lower costs, illustrating that tighter review does not automatically produce savings. The most defensible objective for 2026 is therefore not “deny as many requests as possible,” but “make accurate decisions quickly and measure net benefit.”
How Prior Authorization Produces Savings
Prior authorization is a gatekeeping process used by health plans and other payers to confirm that proposed care or medication is covered and meets plan requirements before payment is approved. For health systems, savings can arise when requests are routed correctly, duplicate or unsupported services are identified, and coding or eligibility problems are resolved before a claim is submitted. For payers, savings can occur when medical-necessity criteria prevent low-value treatment, out-of-network care, or services that fall outside a benefit.
The process can involve several checks, including patient eligibility, provider participation, service coding, clinical documentation, quantity limits, and medical-necessity rules. Step therapy is a related form of prior authorization in which a plan may require an alternative medication before covering the prescribed product. It is intended to control spending and treatment risk, but it can shift costs to patients when the initial alternative is unsuitable. Evidence of savings therefore requires more than comparing authorized spending with denied spending; administrators must also count staff time, vendor fees, interruptions in care, reversals, and patient consequences.
A useful calculation begins with the projected cost of approved services that would not have been medically necessary. From that amount, subtract authorization-system expenses, appeals, delays, reversals, and any provider leakage. Savings also should be adjusted for treatment complications that arise because clinically appropriate care was delayed. This does not mean every delayed case causes harm, but it supports the practical rule that low-risk, high-cost services are better candidates for rigorous review than routine services with a weak cost-benefit case.
Practical Steps for Calculating Net Savings
Organizations should first establish a baseline rather than relying on industry anecdotes. Measure annual authorization volume, average review cost, approval and denial rates, turnaround time, appeal overturn rate, and spending for the reviewed service categories. A common threshold is to examine services with at least $1,000 in expected allowed cost, substantial frequency, and clear clinical rules, while recognizing that even lower-cost services can become expensive when reviewed at very high volumes. A 3% reduction on $100 million in otherwise avoidable spending produces $3 million, but only if the review expense and operational disruption remain below that amount.
Next, compare administrative performance with clinical and financial outcomes. A program that cuts spending by 5% but adds 10,000 appeals, causes a 20% overturn rate, or delays time-sensitive surgery may be economically worse than a more selective program. Track authorization cycle time, full clinical response time, time to treatment, provider rework, member complaints, and adverse operational effects. These measures should be segmented by service, urgency, provider, patient population, and rule version, because average values can conceal serious problems.
Implementation should begin with a limited set of high-value, evidence-based rules and a control group where practical. For example, one organization could compare an imaging rule with historical utilization and a similar unaffected service. Results should be normalized for changes in enrollment, coding, prices, utilization mix, and clinical guidelines. The strongest business case includes avoided spending plus provider and member experience, not just gross denied dollars. This approach also makes an investment case to finance leaders more credible.
Technology, Staffing, and Workflow Options
Technology can reduce manual work, but automation does not eliminate judgment. Rules engines can check eligibility, terminology, documentation completeness, and obvious policy conflicts before a request reaches a clinician. Machine learning may help prioritize requests, but the claim that it guarantees accurate or unbiased decisions would be unsupported. Models need local validation, error monitoring, version control, and a human route for ambiguous or high-risk cases. A 2026 purchasing evaluation should ask vendors for audited performance by service category rather than accepting a general accuracy percentage.
There are several operating models. A centralized team may offer consistent review but create queues and distance from frontline care. A decentralized model uses clinicians close to the request but can produce inconsistent decisions. A hybrid model automates administrative checks, reserves clinical review for exceptions, and assigns clear escalation paths. Provider-facing portals can reduce calls and rework, while bidirectional data exchange can prevent duplicate submissions. These choices matter because a low monthly license price may be offset by high implementation expense or manual exception handling.
| Feature | Manual review | Rules-based automation | Hybrid clinical review |
|---|---|---|---|
| Best use | Small or unusual request volumes | High-volume, repetitive checks | Diverse services with clinical exceptions |
| Main advantage | Human flexibility | Consistency and faster screening | Balances scale with clinical judgment |
| Common limitation | High cost per request | Can miss contextual details | Requires governance and staffing |
| Savings measure | Avoided cost minus labor | Avoided cost minus platform and rework | Net benefit after appeals and delays |
Why More Restrictions Do Not Necessarily Mean Lower Costs
Insurers have stated that prior authorization checks can protect consumers by preventing unnecessary procedures, but the policy objective and measured outcome are not identical. Research and industry discussion increasingly question whether long-standing prior authorization volumes are producing proportionate savings. A request can be denied correctly, yet the eventual care may still occur through another route, changing rather than eliminating spending. Conversely, a fast approval for appropriate treatment may prevent emergency escalation and reduce total cost of care.
The first-of-its-kind spine surgery analysis mentioned in the research context is a useful warning. It associated prior authorization with delays in elective surgery without finding evidence that costs were cut. That finding does not prove prior authorization is ineffective in every category; elective spine procedures may be less amenable to simple preapproval criteria than imaging, pharmacy therapy, or clearly duplicative services. It does show why organizations should evaluate each rule against its own clinical and financial outcomes. Policies that add delay but produce no measurable net savings should be redesigned or retired.
Avoided treatment must also be separated from suppressed demand, delayed diagnosis, or shifted costs. A provider may reduce documentation, appeal an authorization, or use an alternate code, moving the expense outside the original measure. Patient costs can rise through substitutions, higher drug spending, or out-of-pocket exposure. Any credible prior authorization business case should include member access, provider burden, equitable denial patterns, and the rate at which denials are reversed. Restriction is only rational when the expected avoided cost exceeds all these effects.
Common Mistakes in Prior Authorization ROI Models
The most common mistake is calling avoided claims “savings” without subtracting administrative expenses. Another is assuming every denial is permanent. Overturned denials create rework and can indicate that the initial rule was too broad. A third error is using projected savings rather than observed savings and ignoring implementation delays. Organizations should also avoid treating approval speed alone as success; a system that returns an inaccurate decision in two minutes is not operationally superior to one that takes longer but correctly routes the case.
Comparisons become unreliable when organizations use different definitions of net cost, service category, or time horizon. A six-month sample may capture seasonal enrollment changes but not a full year of policy effects. Vendor case studies may count the payer’s gross prevented expenditure while omitting provider labor or patient costs. Independent validation, documented assumptions, and a service-level baseline can reduce these problems. Any target above roughly 5% net savings should be supported by category-specific evidence rather than generalized industry claims.
Organizations must also separate prior authorization from broader utilization management. Some savings attributed to prior authorization may come from coding edits, network management, formulary design, post-service review, or price controls. If those interventions are not separated, an automated platform may receive credit it did not create. This matters for renewal decisions and future rule selection. The correct unit of analysis is the specific authorization rule and its operational effect, not a companywide cost trend.
When to Act, Pause, or Redesign
Action is appropriate when a service is expensive, frequently reviewed, supported by a reliable evidence base, and associated with measurable avoidable utilization. Organizations should also act when current workflows create preventable errors, duplicate submissions, or long queues that can be corrected without increasing clinical risk. A staged rollout is preferable to an immediate enterprise deployment. Start with one category, establish baseline metrics, document the rule logic, and review outcomes after an appropriate observation period.
Pause or redesign a program when denials are frequently overturned, when clinical outcomes are not measured, or when delays are being treated as savings. A time-sensitive procedure, emergency treatment, or narrowly indicated therapy should not be subjected to a complex process merely to increase the raw denial count. A useful governance threshold is to re-examine any rule with an overturn rate above 10%, a sustained increase in appeals, or no measurable net financial benefit after two review cycles. Those are management triggers, not universal clinical standards, and should be adapted to the organization’s risk profile.
The market also changes. News reported in 2024 that some insurers were reducing prior authorization requirements for certain healthcare services, reflecting pressure from providers, patients, and policymakers. A reduction may indicate that a rule produced poor value, but it may also reflect operational capacity, legal change, or a shift in payer strategy. Organizations should treat policy changes as a reason to validate assumptions, not as proof that all prior authorization is ineffective. The most durable approach is selective, transparent, and measured against actual outcomes.
Cost, Pricing, and the 2026 Business Case
There is no responsible universal public price for prior authorization software. Pricing varies with covered service lines, transaction volume, clinical rule depth, data integrations, implementation, support, and whether a vendor provides clinical utilization review rather than software alone. Small deployments may be priced per provider, per request, per member, or per module; enterprise agreements can include implementation and service fees. A quote that appears inexpensive per transaction may become costly once interface work, manual review, appeals, and ongoing rule maintenance are included.
For a simple comparison, a platform fee of $250,000 per year is not automatically cheaper than a managed team costing $300,000 if the platform requires $100,000 in integration and exception work. Both may be justified only if verified prevented spending exceeds total operating cost. A useful business case should show the baseline, conservative case, expected case, and break-even volume. The break-even calculation should include a 90-day implementation window, annual maintenance, clinical labor, and a margin of uncertainty.
As of September 30, 2026, the defensible conclusion is that prior authorization can save money, but the amount cannot be inferred from the phrase itself. The relevant metric is verified net savings after administrative expense, appeals, delays, and treatment effects. Health plans and provider organizations should use a category-specific model, validate claims with current evidence, and revisit rules continuously. Prior authorization is a cost-containment tool, not a savings guarantee, and a selective program is more defensible than a program designed primarily to maximize denials.